The Role of Whey and Lupin in Glycemic Control (Nutritional Pre-Study)

Short-term Effects of Lupin Versus Whey Protein on Glucose and Insulin Responses to a Standardized Meal in a Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02413671

Acronym

NPS

Enrollment

Registered

2015-04-10

Start date

2013-06-30

Completion date

2013-07-31

Last updated

2016-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Whole Body Glucose and Insulin Metabolism

Brief summary

The study compared the acute effects of the supplementation of a standardized meal with either lupin or whey protein or no protein on the whole-body glucose and insuline metabolism.

Detailed description

The nutritional pre-study had the following key objectives: Primary objective: \- Lupin protein lowers the postprandial blood glucose level equivalent to or to a greater extent than whey protein. Secondary objective: \- Lupin protein has an equivalent or a stronger insulinotropic effect than whey protein.

Interventions

DIETARY_SUPPLEMENTLupin Protein

Subjects received a standardized test meal rich in carbohydrates and supplemented with lupin protein.

DIETARY_SUPPLEMENTWhey Protein

Subjects received a standardized test meal rich in carbohydrates and supplemented with whey protein.

OTHERReference

Subjects received a standardized test meal rich in carbohydrates and not supplemented with any protein.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

20 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Female and male volunteers * Age: between 20 and 45 years * Body mass index (BMI): 20-28 kg/m² * Fasting blood glucose within normal ranges (70-99 mg/dl; 29-42 mmol/mol Hb) * Glycated hemoglobin HbA1c within normal ranges (4-6%) * Agreement and signed informed consent before the study

Exclusion criteria

* Diabetes mellitus * Increased bleeding tendency (hemophilia, regular use of anticoagulants) * Allergy to nuts, legume or milk protein * Drug, medication or alcohol abuse (frequent consumption of more than 20-30g alcohol/day) * Intake of medication during the study * Smoker * Competitive athletes * Extreme eating habits (vegan, special diets) * Any other condition classed as unsuitable by the executive medical director

Design outcomes

Primary

Measure	Time frame
Blood Glucose Metabolism by Blood Glucose and Serum Insulin (composite)	up to 180 minutes after the test meal was finished

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026